No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Neurocrine Price Target Announced at $138.00/Share by Needham
Express News | Neurocrine Biosciences Inc : Needham Raises to Buy From Hold
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says